Swedish drug maker Swedish Orphan Biovitrum (Sobi) said on Friday it was in talks with a private equity firm regarding a possible sale of its Partner Products business area.
“We have noted specific information in the market regarding a possible sale of Sobi Partner Products. We confirm that we are in discussions which may or may not lead to an agreement,” Sobi CEO Geoffrey McDonough said in a statement.
Sobi, which has Investor AB as its biggest owner, said the talks did not include drugs Kineret and Orfadin.
Partner Products had sales of 617 million Swedish crowns ($70 million) in the January-September period 2016, while Sobi’s total sales were 3.9 billion crowns.
Sobi rose 2.1 percent at 1402 GMT after an earlier trading halt was lifted. The share was flat before the trading halt.
By Johannes Hellstrom
Source: Reuters
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.